• info@heparegenix.com
  • +49 (0)7071 7912810
  • Sitemap
  • Site Notice
  • Privacy Policy
HepaRegeniX GmbH
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact
Search
  • Home
  • About us
  • Investors
  • Science
    • Liver diseases face an enormous unmet medical need
    • MKK4 – A First-in-class Therapeutic Target
    • Translation into the Clinic
  • Jobs
  • News
  • Contact

Prof. Andreas Busch

p3889712022-11-23T09:34:10+01:00
HepaRegeniX GmbH: Prof. Andreas Busch

Prof. Andreas Busch

Senior Advisor

Dr. Markus Weissbach

p3889712020-11-25T17:30:11+01:00
HepaRegeniX GmbH, Advisor: Dr. Markus Weissbach

Dr. Markus Weissbach

Senior Clinical Advisor

Dr. David Shapiro

p3889712020-11-25T16:20:17+01:00
HepaRegeniX GmbH, Advisor: Dr. David Shapiro

Dr. David Shapiro

Senior Medical Advisor
Get In Touch
HepaRegeniX GmbH: Logo

HepaRegeniX has successfully discovered and developed several drug candidates to combat multiple liver diseases. The first candidate HRX-0215 has recently entered clinical development.

Get in touch

Phone: +49 (0)7071 7912810
Fax: +49 (0)7071 7912809
E-mail: info@heparegenix.com

Address

HepaRegeniX GmbH
Eisenbahnstraße 63
72072 Tübingen
Germany

© Copyright 2016-2020 HepaRegeniX GmbH. All Rights Reserved.